Navigation Links
Pathway Diagnostics Announces Patent Issuance for the Diagnostic Measurement of HIV Tropism for the Initiation or Modification of HIV Therapy
Date:11/15/2007

HIV tropism status needed to initiate therapy with Pfizer's recently

approved Selzentry(TM) (Maraviroc), CCR5 antagonist

MALIBU, Calif., Nov. 15 /PRNewswire/ -- Pathway Diagnostics announces that the U.S. Patent & Trademark Office (USPTO) has issued U.S. Patent number 7,294,458 (the '458 patent) entitled "Analysis of HIV-1 Co-receptor Use in the Clinical Care of HIV-1-Infected Patients." Pathway Diagnostics has licensed the '458 patent (with rights to sub-license) from Health Research Incorporated (HRI), Rensselaer, NY for use in the fields of laboratory diagnosis and monitoring. The '458 patent discloses and claims diagnostic methods for monitoring CCR5 and CXCR4 co-receptor use in the treatment of human immunodeficiency virus (HIV) infection. The '458 patent also claims monitoring CXCR4-specific strain suppression in HIV-positive individuals undergoing highly active anti-retroviral therapy (HAART). Pathway has also obtained licensing rights from HRI for related patent applications, that together with the '458 patent, form the technical foundation of Pathway's SensiTrop HIV tropism assay.

"The patented technology underlying Pathway's SensiTrop assay is a significant innovation that enables HIV treating physicians to select the appropriate treatment for patients using a proprietary molecular assay that is fast and affordable. Pathway's partners have recognized the strength of Pathway's patent portfolio and the importance of these patents when testing CCR5 and CXCR4 co-receptor use for HIV therapy," stated Walter Narajowski, CEO of Pathway Diagnostics.

About HIV Co-receptor tropism and the SensiTrop(TM) assay

The ability of the HIV virus to infect different cell types utilizing different cell surface receptors is referred to as HIV co-receptor tropism. One type of HIV that utilizes the CCR5 co-receptor has been shown to be blocked by CCR5 antagonist drugs such as Selzentry. A different type of HIV that utilizes the CXCR4
'/>"/>

SOURCE Pathway Diagnostics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
2. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
3. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
4. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
5. Strategic Diagnostics Updates Roth Conference Presentation Time
6. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
7. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
8. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
9. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
10. BoVir(R) Named Best New Veterinary Diagnostics Product in International Animal Pharm Awards
11. Enigma Diagnostics Announces a European Commission Award of EUR3 Million to Fund the Development of a Point of Care Platform for the Rapid Diagnosis of Influenza Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Based on the revenues gained ... market is dominated by four major players contributing ... These players include GE Healthcare (U.K.), Siemens AG ... , Full Report Copy at http://www.marketsandmarkets.com/Market-Reports/surgical-imaging-market-210534462.html ... be attributed to its strong product portfolio, which ...
(Date:12/17/2014)... 17, 2014 Once more, EMAAR ... larger packaged waste water treatment plant to phase one ... City (KAEC). Two years ago Bioshaft successfully supplied and ... serving two residential towers with an occupancy of 900 ... quarter million gallons per day and was signed on ...
(Date:12/17/2014)... 17, 2014 Audacity, a leading California-based ... member of the Huntsworth Health Group, is proud to ... team. In her role, Gonzales will serve as Senior ... incredibly honored to welcome a talent of Jamie’s caliber ... Gaëtan Fraikin. “She is a proven healthcare innovation leader ...
(Date:12/17/2014)... FRANCISCO, Calif. , Dec. 17, 2014 /PRNewswire/ ... of a Phase 2 study evaluating the investigational ... treatment of patients with severe, chronic itch who ... standard of care, including topical steroids and antihistamines. ... percent change in Visual Analog Scale (VAS) itch ...
Breaking Biology Technology:Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
... May 16, 2011 Palatin Technologies, Inc. (NYSE Amex: ... dysfunction indications and PL-3994 for acute asthma and other indications, ... 2011. Recent Highlights ... Administration (FDA), Palatin submitted a revised protocol to the FDA ...
... May 13, 2011 InterMune, Inc. (Nasdaq: ... results from two Phase 3 trials demonstrating that treatment ... associated with favorable effects on lung function, 6-minute walk ... mild to moderate idiopathic pulmonary fibrosis (IPF).  IPF is ...
... Novavax, Inc. (Nasdaq: NVAX ) a clinical-stage ... of Novavax, will be presenting at the NOBLE FINANCIAL 7th ... The Hard Rock Hotel, Hollywood, FL.  A live audio-only webcast ... website at www.novavax.com under Investors/Events. ...
Cached Biology Technology:Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results 2Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results 3Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results 4Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results 5Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results 6Pirfenidone Phase 3 Results Published Today in The Lancet 2Pirfenidone Phase 3 Results Published Today in The Lancet 3Pirfenidone Phase 3 Results Published Today in The Lancet 4Pirfenidone Phase 3 Results Published Today in The Lancet 5Pirfenidone Phase 3 Results Published Today in The Lancet 6
(Date:11/18/2014)... 17, 2014 The Parenteral Drug Association (PDA) today ... will speak and at least seven more will participate in ... Omni Shoreham Hotel in Washington D.C. , ... have significant support from the regulatory agencies in ... in our effort to help advance the use of ...
(Date:11/15/2014)... NEW YORK , Nov. 13, 2014  While we ... of technology Doctor McCoy used in "Star Trek" to gain ... and tools designed to work with smartphones and tablets for ... corners of the healthcare world. This may seem a tad ... are ready to adopt some of these technological opportunities into ...
(Date:11/11/2014)... 11, 2014  Forensicon, Inc., a Chicago ... to announce the promotion of Yaniv Schiff ... Forensics. In Schiff,s new role as Director, he will ... digital forensics examiners and provide leadership within the company,s ... http://photos.prnewswire.com/prnh/20141110/157719 Schiff joined Forensicon ...
Breaking Biology News(10 mins):FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2
... can pay big dividends to aging baby boomers who want ... division of geriatric medicine at Saint Louis University, in a ... of life as we age. Living well and feeling ... your lifetime is priceless, says Morley, who is coauthor of ...
... have devised a novel way to create tiny colonies ... organ. The work could allow better screening of new ... reduce the costs associated with their development. Liver ... pull drugs off the market. These dangerous drugs slip ...
... NASA study estimates that most ground-level particulate pollution in ... America and only a small amount is brought to ... Researchers using an innovative global aerosol tracking model have ... sources and movements of aerosols near the ground where ...
Cached Biology News:Eat chocolate, drink wine, add fun to life: SLU geriatrician shares secrets of staying young 2Eat chocolate, drink wine, add fun to life: SLU geriatrician shares secrets of staying young 3Eat chocolate, drink wine, add fun to life: SLU geriatrician shares secrets of staying young 4MIT: 'Micro' livers could aid drug screening 2MIT: 'Micro' livers could aid drug screening 3Local sources major cause of US near-ground aerosol pollution 2
Screening test for the detection of Salmonella sp. by means of DNA amplification, subsequent molecular hybridization and detection on a microtitre plate....
... three step procedure (PCR, Exonuclease III digestion ... one day. The typical cloning efficiency using ... Features and Benefits: , , Universal - ... expression vector , High Cloning Efficiency - ...
... or 384-well PCR plates Dimples on both sides ... plates End tabs on Thermo-Mat™ 384 fit into ... sealing is achieved with either Thermo-Mat™ 96 or 384 ... lid thermal cyclers Fully autoclavable May ...
... HistoMark Biotin Streptavidin-HRP Systems provide rapid, ... intracellular antigens in frozen or paraffin-embedded ... These systems also facilitate double or ... be performed simultaneously with primary antibodies ...
Biology Products: